This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: We're seeing customers waiting to order insecticides and fungicides until they observe best in the field. In Latin America, sales were up 14%, mainly from volume growth in Brazil. The region also showed strong gains in new products, including Corajanivo and previous tar-diamide insecticides, Borough Food and StonerBesides and Onsuba, a newly launched fluentapyr-based fungicide. Lower price was driven by three factors I mentioned earlier, competition in the market, strategic pricing on less differential products, and one-time price adjustment. Air sales were down 28%, and that was largely driven by volume in India. Channel volume in India remained high, especially in insecticide, which has built up over successive poor-mansion seasons. Sales of generic runoxapyr are acting as a smaller secondary headwind while we pursue litigation for process pattern infringement. Ronaldo will speak more to the diamides in a few minutes. We do not see the India channel inventory resolving until at least 2025. In other areas of Asia, Asian countries reported the strongest growth while China declined. Sales in the MEA were down 3%. Excluding sales to a diamide powder, the region reported overall sales growth in the low 10% driven by volume. The region delivered strong growth in branded diamides and fungicide. Looking at the EBITDA bridge on slide five, we delivered EBITDA of $202 million, which is at the highest end of our guidance range. The increase of 8% versus the prior year was due to volume growth, cost benefits from our restructuring actions, and FX tailwinds. These three factors, more than offset, lower pricing and coaxed wind related to the sale through of higher cost inventory. Slide six provides an update on the progress in our restructuring actions. We are making excellent progress and have already realized considerable cost benefits through June. We now expect between $75 million to $100 million of cost benefits in 2024 net of inflation and our own pace to achieve over $150 million of gross run rate savings by 2025. On July 11th, we announced that we entered into an agreement to sell a global specialty solution business for $350 million to end you. We're expecting the transaction to be completed by the end of the year. We will continue to include the results of this business in our reported figures until the deal has closed. As it does not meet the criteria to be moved into discontinued operations. Her guidance for the second half includes earnings and cashflow from this business. Looking ahead to the rest of the year, we have updated a full year revenue guidance to a range of $4.3 billion to $4.5 billion, which is 2% lower than prior year at the midpoint. This is 200 million dollars reduction between the midpoint over new and prior gallons. And about half of that attributed to lower first half sales that we do not expect to make up this year. The remaining reduction is mostly the results of a slower than expected demand recovery. Although demand recovery is slower than originally anticipated, we do not see improvement in most geographies. Sorry, we do see improvement in most geographies with the exception of India. A revised EBLA guidance of $880 million to $940 million reflect the lower revenue outlook and the 7% reduction at the midpoint against prior gallons and prior year. We expect third quarter revenue to be between 1 billion and 1.09 billion dollars, which is 6% higher at the midpoint versus prior year. Volume is the key driver with pricing expected to be down low single digits. Year over year pricing headwinds are lower compared to the second quarter as we do not plan to continue one time incentives now that much of the high cost inventory in the channel has been reduced. Overall pricing levels in the third quarter are expected to be similar to the second quarter. Third quarter EBLA is expected to be between 165 million dollars and 195 million dollars, representing 3% growth at the midpoint. EBLA margin midpoint of 17% reflects the outsized impact over 40 million dollar COGS headwind we expect during the quarter. The headwind is mostly attributed to unabsorbed six costs related to reduced manufacturing during the second half of 2023. Absence of this headwind would put our implied third quarter midpoint EBLA margin in line with the historical Q3 average. Fourth quarter revenue is expected to be between 1.34 billion dollars and 1.45 billion dollars, which is 22% higher at the midpoint. Volume is expected to be the key driver of sales supported by new products, improving demand and growing market share. Price and effects are both expected to be low single digit headwinds. Fourth quarter EBLA is expected to be between 353 million dollars and 383 million dollars, but 45% at the midpoint, almost entirely attributed to higher sales. Costs are expected to be favorable from restructuring benefits. The quarterly pace of results this year is forecasted to be different from what we reported in the past. Typically, the third quarter is the lowest revenue quarter in the year. This year, it is expected to be higher than the first and second quarters due to the timing of the demand recovery. Our second half revenue split between Q3 and Q4 has historically been about 46% third quarter and 54% fourth quarter. This year, we are getting to a quarterly revenue split in the second half of 43% third quarter and 57% fourth quarter. The higher than usual sales in Q4 are due to the shape of the demand recovery. To achieve the midpoint over a four-year balance, we expect to grow in the second half by 15% revenue and 28% EBITDA with a strong fourth quarter. There are four reasons we are highly confident in those numbers. One, there are signs that demand is recovering. Our second quarter volume is evidence of that. What we're seeing in our second half order books also reflects that improvement. For example, in Brazil, we have about a third of the orders in our book that we'll need to reach that country's second half targets. At this time last year, it was almost zero. Early indications after one month of second half operation showed that the regions are on track to reach their targets. Two, a large portion of the sales growth we expect in the second half is coming from product launched in the last five years. We see solid demand for these products due to their differentiation from older technologies. Some examples include consorga, fungicide, and coragen, evo, insecticide in Latin America. Overwatch herbicide in Asia based on the new active ingredient, isoflex, and new diamite formulation in North America like elovest and alzacore evo. Three, improve orders from our diamite partners. Similar to FNC, our partners have been attempting to work down high level of inventories. Levels are now reaching a point that are supporting our purchases. And four, cost management. We have shown the ability to effectively control costs and deliver on a research during savings commitment. They will continue in the second half. I will now hand the code over to Andrew to cover some financial items, including a cash performance and outlook.
spk08: Thanks, Pierre. I'll start this morning with a review of some key income statement items. FX was a 2% headwind to revenue growth in the second quarter, with the most significant headwinds coming from the Indian rupee, Brazilian Riai, and Turkish lira. For the remainder of 2024, we anticipate continued low single digit FX headwinds driven primarily by the Brazilian Riai. Interest expense for the second quarter was $63.6 million, down slightly versus the prior year period, but lower foreign interest expense offsetting higher domestic interest expense. For full year 2024, we expect interest expense to be in the range of $235 million to $240 million, essentially flat year on year at the midpoint, with the impact of higher rates on domestic debt offset by lower foreign boroughs. Our effective tax rate on adjusted earnings for the second quarter was 15.5%, in line with the midpoint of our continued expectation for a full year tax rate of 14 to 17%. Our gap provision for income taxes in the second quarter benefited from the transfer of intangible assets to our Swiss subsidiaries, where we recently were awarded OECD Pillar 2 compliant tax incentives. This asset transfer will allow us to take further advantage of these new incentives, and will help ensure FNC maintains a structurally advantaged tax rate for at least the next decade. Moving next to the balance sheet and leverage. Gross debt at June 30th was approximately $4.2 billion, down $157 million from the prior quarter. Cash on hand increased $54 million to $472 million, resulting in net debt of approximately $3.7 billion. Gross debt to trailing 12-month EBITDA was 5.3 times at quarter end, while net debt to EBITDA was 4.7 times. Relative to our covenant, which measures leverage with a number of adjustments to both the numerator and denominator, leverage was 5.4 times as compared to a covenant of 6.5 times. As a reminder, our covenant leverage limit was raised temporarily to 6.5 times through June 30th of this year. It will step down to six times on September 30th, and then again to five times at December 31st. We expect covenant leverage approaching four times by year end, reflecting both -on-year EBITDA growth in the second half, as well as receipt of proceeds from the recently announced sale of our Global Specialty Solutions business to InView. We remain committed to returning our leverage to levels consistent with our targeted triple-B, BAA2 long-term credit ratings, or better. While we will still be meaningfully above this level at the end of 2024, we are confident that with EBITDA growth and disciplined cash management, we can reach leverage metrics consistent with our target credit rating in 2025. Moving on to free cash flow in slide 11. Free cash flow in the second quarter was $280 million, an improvement of over $187 million versus the prior year period. Nearly all of this improvement came from adjusted cash from operations, which improved by $184 million from a reduction in inventory, as well as a build of payables. Collections continued to be strong and ahead of our internal forecast. Capital additions were low, and we were lower as we continued to constrain investment to only the most critical high-return projects. Legacy and transformation cash spending was up due to the costs related to our restructuring program. Through the first half of 2024, free cash flow is up $915 million versus the prior year. We now expect free cash flow of $400 million to $500 million for full year 2024, a positive swing of nearly $1 billion from the 2023 performance at the midpoint of the range. This -on-year increase is expected to be driven by significant cash release from rebuilding accounts payable and reducing inventory, partially offset by higher accounts receivable due to revenue growth in the second half of the year. Relative to our prior guidance, this free cash flow outlook reflects the updated EBITDA guidance provided today, as well as a modest reduction in anticipated capital investments. With that, I'll hand the call over to Renaldo.
spk05: Thank you, Andrew. Before I begin, I want to take a moment to describe the four components that drive our portfolio's growth. The first is innovative formulations of our non-diamite products, some of which are patented. The second is our diamite franchise. Growth of the diamites is supported by existing IP protection and our actions to transition to unique patented formulations. This is enabled by our extensive knowledge of the diamites and their target insect populations. Third is bringing to market four new active ingredients, with two having a new mode of action and a new family of products, the pheromones. Finally, our expanding platform of biological products. Today, I'll focus my discussion on diamites and the new active ingredients and what gives us confidence in our ability to keep growing. Diamites have been a core part of our business since we launched FMC as a peer-play agricultural sciences company in 2018. In these almost seven years, we have grown our partner base and expanded our geographic footprint. Through new product registrations, we have introduced brand new patented formulations that allow us to enter new market and crop segments. From the time we purchased the diamites, there have been concerns regarding a perceived cleave on revenue. This is absolutely not how we see it. Rather, we expect the diamites to be a growth platform for FMC well into the future. Discussions about the strength and resilience of our diamites usually start with the composition of matter patents for the active ingredients. These have largely expired for renaxapyr and cyasapyr active ingredients. But there are many other factors that support the strength of our diamites. One such factor is other patents, which includes manufacturing processes and specific intermediates. These patents provide protection that continues through mid-2026, varying by-product and geography. In countries like India and China, these patents have been harder to enforce, which is not the case in most other geographies. This is evidenced by recent legal victories and the lack of generic players attempting to sell in these other geographies. Another factor is data protection. Providing studies for necessary registration can be time-consuming and costly for competitors. If a generic player wants to reference our proprietary data to save costs and time in registering their own products, they will need to wait until the data is no longer protected, which can be as long as 10 years from the original registration. We sell our diamites in nearly 100 countries. Each country has its own regulatory agencies, and the time to register a generic can vary from one year in some countries to more than five years in others. As such, in many countries, competing companies are prevented from registering a generic version of our Siazapur active because FMC's data protection has not expired. After all composition of matter, process and intermediate patents and data protection expire, we know that generics will come to the market, most with solo-diamide products that mimic our original products. What they will find is that FMC has not been standing still. We have been actively working to advance our diamite technologies through new formulations. First, through the development of new and in many cases patented solo-enhanced formulations. Solo formulations are renaxapur or siazapur molecules formulated to be convenient to farmers, more sustainable and more cost-effective, allowing FMC diamite products to be more competitive while remaining highly profitable. These new enhanced solo formulations that we are now introducing in the market are often patented and include high concentration and solid formulations, such as the large effervescent granule product we showcased at our November Investor Day. The second and most important advancement stems from our innovation in developing mixture formulations, which combine diamides with complementary active ingredients. These mixture formulations not only mark a substantial leap forward in performance for growers, but also play a crucial role in preemptively addressing potential insect resistance. At FMC, our proactive approach involves extensive monitoring of insect populations through molecular biology, allowing us to anticipate and mitigate resistance issues. Our expertise in this domain informs the development of superior products tailored to meet the specific needs of each key market. Because we own these products, we have more knowledge about the diamides than any other company, and we are using this knowledge to create superior products. This work is highly tailored to each key country, which again, significantly diminishes the likelihood of any sudden widespread impact on sales. Simply put, we are confident that there is no impending revenue cliff for these key assets. There are layers of protection for both Rhinoxapir and Siazapir-based products, making them an important growth platform for FMC for years to come. We have talked about the diamides many times over the last year. To recap the key points, our current patent state is strong and will remain in place for some time. We are successfully defending our patents and will continue to enforce our IP. We are extending and further protecting the lifecycle of diamides through new formulations to ensure our portfolio remains convenient to growers, highly cost-competitive, and performance-differentiated. Today, we are developing and launching products that will be needed to help fight insect resistance now and in the future. FMC is best positioned to do that because we have consistently used advanced techniques to monitor insect populations for years. These are the reasons why we believe that diamides will continue to be a meaningful contributor to FMC's growth throughout this decade and beyond. In addition to the diamides, the continued introduction of new molecules and new formulations will support our long-term growth. This includes the launch of four new active ingredients, which we spoke about during our 2023 Investor Day. Fluindapir, a patented fungicide that we have recently launched in the US, Paraguay, Argentina, and Brazil, with future registrations expected for Mexico and India. This product gives us access to the large corn and soybean fungicide segments, where we played only marginally until recently. Isoflex, the herbicide we launched in Australia and Argentina. Isoflex will also be launched in Brazil later this year and continue to expand into other crops throughout 2025. In India, we just received product registration this week and plan to launch soon. In Great Britain, we have received the active registration and anticipate product registration shortly. Dodelex, a patented rice herbicide and the first herbicide with a new mode of action in over 30 years. We have submitted regulatory registration in seven countries, in which these make up close to 30% of the global rice market. Commercial launches are expected in 2026. Dodelex is a big innovation in rice, and as we advance its development, we continue to find new opportunities on additional crops. Remizoxifan is still in its earlier stages. Remizoxifan is an exciting herbicide, effective against resistant weeds like Palmer amaranth in corn and soybean markets. It's another unique product with a new dual mode of action. Finally, pheromones, a platform of products that can potentially change the way growers manage and protect their crops from insects. We have already applied to register the first pheromone product for row crops in Brazil, Mexico, US and Philippines. We estimate this product platform will contribute about one billion dollars in revenue by 2033. Years from now, when solo-diamide products are fully exposed to the market, in the market, we expect that FMC will be well beyond those original products with patented new formulations and innovative diamide mixtures. Regarding the five new products I have just mentioned, two have launched, two are waiting registrations, and one is pending regulatory submission. Combined, these products will give us access to segments we do not play in today, significantly expanding our addressable market in the future. Our growth story is one of innovation. It is strongly rooted in the strength of our current portfolio and the significant growth we anticipate from our new products. These are sales that will be in addition to our legacy portfolio, including the diamides. I will now turn it back over to Pierre.
spk01: Thank you, Ronaldo. Before we move to Q&A, I want to make a few high-level comments on 2025. It is too early for any formalised guidance, but I will share some factors that we believe could influence our results. We're expecting demand in the market to continue to accelerate from where we end 2024. That would lead to volume growth for FMC, especially in the first half of the year where prior comps will be weaker. We also expect continued strong growth of our new products. Pricing is uncertain, as in the case during any period of demand recovery. The pricing actions we've taken this year should position us well in 2025. Overall, we expect 2025 revenue growth at around 6% excluding the GSS business. On the cost side, there is about 150 million dollars to 200 million dollars in expected favourability. That's coming from lower raw materials, the absence of an absorbed fixed cost headwinds that is forecasted in 2024, and a full year of restructuring benefits. There is some uncertainty depending upon how raw materials move, but overall the 2025 cost story is shaping up to be positive. The cost favourability will be partially offset by the loss of about 30 to 35 million dollars of EBITDA from the sale of the GSS business. That gives us growth at the top and bottom line in 2025, with further growth coming in forward years as the new product in a pipeline that Ronaldo spoke about and expand into new countries and markets. With that, we are now ready to take your questions.
spk03: Thank you. We will now begin the question and answer session. To replace the queue, please press the star key, then 1 on your touch-tuned phone. If you are using a speakerphone, please pick up your headset before pressing the keys. Please limit yourself to one question. If you have any additional questions, you can jump back into the queue. To withdraw from the queue, please press star, then 2. At this time, we will pause momentarily to assemble our rooster. The first question comes from Chris Parkinson from Wolvi. Your line is now open.
spk07: Thank you so much for taking my question. As much as I would love to focus on some of the intermediate and longer-term factors which you have been highlighting on a preliminary basis, I would love to just dig in a little on the second half and the cadence between the third and fourth quarter. The ag markets are still pretty difficult. There is still some uncertainty in Brazil. Any color you could offer to give investors a little bit more comfort on the split there, and the puts and takes that you outlined on slides 8 and 9 would be especially helpful. Thank you so much.
spk01: Thank you, Chris. I'm going to try to be concise on the answers, but I might be a bit longer on this one because I think it's the right question. The sequence is important. Q4 is an important quarter. First, I'm going to make an answer which is not a business answer. I'm just back. I do not need to take a risk as a CEO just back to miss my first two quarters. I could have gathered a different level. Nobody would have been surprised with a full year guidance at $890 or $900. So if I gathered where I did for the fourth quarter, it's because I did a very strong due diligence. And it's a true bottom-up process. We went through to define sales and earnings. For Q4, we have a much improved visibility today in Latin America and mostly Brazil, in North America, and in EMEA. As an example for Brazil, we believe that the orders we already have in hand and the Q2 action to prepare for the season put us in an excellent position to meet the Q3, Q4 targets. North America, I'd say the visibilities is good for the short term. It's an easier market to forecast short term in a sense that we have fewer customers. They are mostly large distributors. So it's a much easier place to define your short term potential sales. I would say that the least comfortable in terms of visibility for us would be Asia, driven by the channel situation in India. And I can tell you that that has been reflected in the way we have been forecasting the quarter, the fourth quarter. Third point I would make is the channel is getting closer to normal and demand is picking up. Additionally, we know and we've seen and we've talked to customers and we know some of the customers have pushed Q3 demand into Q4. They're buying as late as they can. So that is inflating the Q4 sales number. On the price, we do not see risk. We have taken very strategic decisions, bringing a price down in the second quarter. We have reposition pricing that's being proven by the volume we're able to reach in Q2. So we believe Q3, Q4, we should see price quite quite slight versus Q2. And we we do not see many risks, especially in Latin America. Finally, and most importantly, in the second half, 60 percent, 60, 60 percent of the growth in the second half is new product introduction. This is actually quite in line with what we saw in Q2. The demand for those products, some of them which were introduced in and market tested in 2023 is very strong. Importantly, it gives us access to market we did not have access to. So that is a very large component over H2 and Q4 growth. Maybe Ronaldo, you want to say a couple of words about the new product we're introducing to give some confidence about Q4 forecast?
spk05: Sure, Pierre. The I would highlight to in in the US, we're talking about these enhanced formulations of the diamonds as well as some herbicide platforms that continue to grow for FMC. We just launched a Dadaastro pathundice site in North America, and that is gaining a lot of esteem and speed. And in South America, particularly, we're very excited with introduction of the fluine, the peer based on Suva, a fungicide that puts us to play in the soybean rust segment. And and also we don't talk much much about that, but there are two new formulations of our so phantasm franchise that are also growing fast in in Latin America, particularly in Brazil, one for sugar cane borofo and the other one more on the control to control resistant weeds on soybean in Brazil. That is a stone, as Pierre mentioned.
spk01: So in a few words, I'm going to say it again. Trust me, I don't want to miss neither Q3 or Q4. So there is a very solid due diligence behind the behind those number and and strong confidence.
spk07: Excellent color. Thank you so much.
spk01: Thanks, Chris.
spk03: Thank you. The next question comes from Josh Spatter from UBS. Your line is now open.
spk11: Good morning. I was wondering if we talk a little bit on the cost side of things a little bit more. So you talked about a headwind in three Q from some higher product costs due to the downtime you took later last year. When do you roll through that? So is that a tailwind in the fourth quarter? Is that a more of a tailwind into next year? And I guess any other weird cost movements we should be thinking about between three Q or four Q that maybe drives some higher confidence in that four Q pickup.
spk08: Hey, Josh, it's Andrew. I'll take this one. I think certainly two threes have been an aberration just that the lumpiness of how some of this cost is flowing through. Just a reminder, we do have raw material cost benefit throughout the year for newly purchased materials. We've had headwinds that offset that in different ways throughout the different quarters. As we look to the third quarter, the big issue is a big slug of unobsorbed fixed costs that are now flowing through our P&L from downtime we took in manufacturing facilities in the last year. That is really the big offset to raw material cost favorability. We do also have a little bit higher distribution and freight costs because we're doing higher volumes, but it's really that flow through of the unfavorable variances. In Q4, we still have a little bit of those volume variances flowing through that unobsorbed fixed costs flowing through. We do have higher distribution costs, but we still have raw material cost favorability from the prior year. So gross margin costs become much more of a flat issue in Q4. Some of the additional benefits of total costs, you'll see a modest tailwind on overall costs in Q4 with restructuring benefits and a lack of a headwind on cogs. Q3, it's the carryover of unobsorbed fixed costs from last year. It's lumpy. It's flowing through. This is the last big slug. Unfortunately, it's large enough to where it offsets any of the restructuring benefits year on year in Q3. In Q4, we get out from under the biggest pieces of that, and the cogs headwind gets to be pretty flat.
spk11: Got it. Thank you.
spk03: Thank you. The next question comes from Vincent Andrews from Morgan Stanley. Vincent, your line is still open.
spk09: Thank you, Andrew. Maybe I'll just follow up on that. On the foreign exchange impact on the back half of the year, if I read this right, Q3 has a revenue hit from foreign exchange, but it's a tailwind to EBITDA. And then Q4 also has a hit on the revenue line, but it seems to be neutral on EBITDA. And can you just update us on how that flow through works, or is there something sort of specific to the second half and some of the issues that you mentioned in terms of timing of raws and inventory flow through this may be impacting this as well?
spk08: Yeah, thanks, Vincent. Now, it's really more of an issue in SG&A and RD, quite honestly. The currencies that are just the most in play in those quarters. And it's a basket of currencies, but in Q4 in particular, it's the REI. And while we have a revenue headwind, it's an SG&A benefit. So net-net, we end up with a minor tailwind to EBITDA in the fourth quarter. But we wanted to highlight that because it might not, given that it's a modest low single digit FX headwind at revenue, we didn't want to missignal people that it would actually go the other way in Q4. So it's really, it's which effect, which currencies are hitting and the fact that there are benefits in SG&A from those currency changes that offset what happens at revenue.
spk03: Thank you. Thank you. The next question comes from Aaron with Bonifant from RBC Capital. Your line is now open.
spk10: Thanks for taking my question. Good to speak with you guys and good to hear you again, Pierre. So I guess my question is really around some of the learnings that you've unearthed and maybe some of the topics you've touched on earlier as far as due diligence. Were there any personnel changes other than yourself? And do you think that's necessary? And then maybe you can also highlight the -to-market strategy in some of these areas. I mean, obviously the credit issues were a factor in South America last year that potentially exacerbated some of the de-stocking that you've seen. Yeah, maybe you can address those issues. Thanks.
spk01: Sure. In terms of personal issues, people, I think the team is in place. We are well organized. Due diligence, I think what I've been looking deep into is a forecasting process, selling process, and execution. I think it's pretty clear that we've missed quite a few quarters where we've missed our own selling target. And I think that's a place where we need to be highly vigilant. And Ronaldo and myself were looking deep into that. And I can tell you that I spent a long, long time with each of the four regional presidents to validate the forecast for Q3 and Q4. Another topic where I see a change I would like is regarding Diamides. I think a Diamides franchise is good. I think we do have very interesting solo and mutual formulation. We need a more aggressive Diamides global and regional marketing strategy. We also need to accelerate new product invention for Diamides. So that is also a place where I'm going to be looking into very carefully. And we have started to do some work. I'd say point number three, I am, of course, pleased with the results of the restructuring program. I still believe we are operating at a cost which is too high. The corporation is back to the sales number of 2018-2019. But we have a cost structure which is more of a 2022 cost structure, 2023 cost structure. So no need to implement a new restructuring program. But I can tell you there is attrition, which if it's used strategically, can truly lower your cost of operation and very quickly at no cost. So that's kind of a part we are looking into right now to lower our cost. Maybe last, I'm quite pleased with the R&D organization, the output. But I still want to have maybe a stronger coordination between the work which is done in the regions and at the global level to have an even more efficient R&D organization. So some of the places where I'm focusing my attention right now. The strategy of the company is in place, is solid. I'm not planning major change, but execution and short-term marketing strategy is important. Andrew, you want to address the question on Brazil?
spk08: Yeah, look, Arun, I'd say simply this. Certainly, the availability of credit to our customers did impact perhaps some buying last year. But I would emphasize the quality of credit in our own receivables is very high. Our provisions, our past dues are down. Our collections have been ahead of our own internal forecast. So while that availability of credit may be a rate limiting step on purchases, particularly last year when there was such the heat of the correction, we don't believe that that's either a risk to our revenue or a risk to our balance sheet at this point.
spk10: Great, thanks a lot.
spk03: Thank you. The next question comes from Frank Mitch from Vimeo Research. Your line is now open.
spk06: I guess good morning and yes, Pierre, good to hear from you again. And I really appreciate the answer to the first question, given that there was some sense perhaps that the 4Q guide, was more on the aspirational side and clearly you don't believe that to be the case. You indicated that one of the things that gives you confidence is that in Brazil, a third of the order book is already booked as opposed to last year where it was zero. I'm curious as to what that typically is, because obviously last year was an anomaly. So what is more normal? So we have a kind of a benchmark there. And also, you know, obviously on the cost side, you know, you're doing a lot of work and I noticed SG&A was particularly light in the second quarter. If you could give us some color as to what your expectations are on the SG&A side as we progress through the year and into 2025. Thank you.
spk01: Sure, thanks, Frank. The first question. Normal pace. Oh yeah, normal pace, sorry. Yeah, we have about 30, quality 35% of orders. Last year was zero. I would say that in period of high demand, when your markets are growing at strong pace, a 45% up to 50% of orders in hand would be a normal ratio. You could expect, I'm talking when you have a very healthy market with low inventory in the channel. I think the numbers you've seen are not much different from what we said in the script. I think we were increasing north of 75 million dollars, the target with the large part coming from SG&A. I do believe that we're going to reach the 150 million dollars by the end of 2025 in run rate in overall cost saving with a significant part coming from SG&A. But once again, I want to emphasize as much as 150 million dollars, whether it's on the COGS side or the SA&R side is a good number. We're going to need to do better. We're going to need to do better. We're going to need to operate at lower cost. And we have in place a strategy program around nutrition because that's an opportunity for us. We have tools which allow us to work differently. And I think we have to use them.
spk06: Thank you so much.
spk03: Thank you. The next question comes from Richard from Wells Fargo. The line is now open.
spk12: Great, thanks and welcome back, Pierre. My question basically is bigger picture in terms of Pierre, coming back to the industry and looking at where the industry has gone. We saw peak earnings in 2022. Obviously, you've done some restructuring and some divestitures. I was just wondering what your thoughts are in terms of where we are in the cycle, given where crop prices have been moving weaker through 2024. And then I know you gave some high level comments around 2025, but just curious in terms of when you can we see an inflection point in terms of pricing getting better. And do you really think we are at the trough here in the second half of 2024?
spk01: Yeah, I think we've, you know, the cycle we've seen them before. There is always the seven, eight years of growth followed by one to two year down cycle. Every indication we had, and we tried to be very scientific and maybe more than usual in analyzing the market. We believe we reached the bottom in Q2 2024. That being said, we do not see getting back to a more normal business activity and a more normal channel until the first quarter of 2025 for Latam, Europe and North America. I think for Asia and mostly driven by India, we're going to have to wait well into 2025 to have more normal activity. I believe by the end of 2025, we are off the down turn. Mostly, mostly the recovery is going to be driven by non-Asia regions in the first quarter of 2025.
spk03: Thank you. We have our next question comes from Alan Rodriguez from Missouho. Your line is now open.
spk04: Thank you. Good morning, everyone. So one quick question. I mean, I think in terms of pricing, I think you mentioned in the opening remark about like the strategic intent to lower prices to regain the less differentiated products. That was a key driver of the lower prices. I mean, the question that I have is why the shift in strategy there? And also, how is that going to improve margins? I mean, are you chasing volume at the expense of profitability? If you could address that a little bit,
spk01: please. Absolutely. I think we acknowledge that we were aggressive on pricing to recover raw material cost increase. This period of inflation in cost is now mostly behind us. But we intentionally kept prices at a very high level across the board because we saw a market where demand was poor. There was no real demand. So fighting with price in time when there is no demand, we felt was not the smartest thing. But we also have to face that now we have more than recovered our cost through the period of raw material inflation. And we do have a tool to take back position we should have and get back to market share we had in places where we've been artificially keeping price high, even if there was no differentiation. So it is not a change of strategy. It is not we're not going to become a company which is going to be chasing volume at any cost. I think we used Q2 to reposition prices in order for us to be able to grow and benefit from the growth of the market. But this is it. You will not see us continuing this in Q3 or Q4. But I have the feeling that we needed that repositioning of pricing after quarters of aggressive price increase. But absolutely no change in the strategy, no chasing of volume at any cost and not. We're not going to pay less attention to the margins of the gross margin or EBITDA margin of the company.
spk04: Thank you.
spk03: Thank you. Our last question comes from Benjamin from Barclays. Benjamin, your line is now open.
spk02: Oh, yeah. Good morning and thanks. Thanks for squeezing me in at the end. I just wanted to follow up real quick on some of the promotional activity that you've mentioned, what's happening in India and how that's impacting anything you can share on like how consumers or farmers are reacting to that. And if that if there's any risk of overstock in the future, given those discounts that you're putting in. Thank you very much.
spk01: If I understand well the question you're asking about the one time incentive we gave to our customers, Listen, our customers and Brazil, to some extent in North America, We're holding high cost products and and those products were stocking the channel. We needed to see those product move through the channel to go to the end customers. And and we had discussion with them. They needed help. We helped them and that allowed us to to free space with a product going on the ground and moving through the channel. So it's it was very clear with them. It's a one time incentive, which is done toward the end of a down cycle. Customers need help. We were there for them. It helped us to for the following of the year and it's cleaning up the channel. I think everybody's clear on the market on why we why we do it. I don't think there is any any risk of channel stocking because our prices right now as well, they should be. And I'm not lower than than what the market is commanding.
spk02: Thank you very much. Thank you.
spk03: This concludes the FMC Corporation Conference call. Thank you for attending. You may now disconnect.
Disclaimer